成人造血细胞移植后T细胞恢复延迟与总生存期降低相关
该研究纳入2008至2019年因急性髓系白血病、急性淋巴细胞白血病或骨髓增生异常综合征接受首次异基因造血细胞移植并上报国际血液与骨髓移植研究中心的2089例患者,分析第100天和第180天CD4计数与结局的关系。成人第100天和第180天CD4计数高于 cutoff 与总生存期、无进展生存期改善及治疗相关死亡率降低相关,但未发现与复发、感染发生率或慢性移植物抗宿主病的关联;儿童患者未发现临床关联。
要点
- 成人第100天CD4计数与总生存期、无进展生存期和治疗相关死亡率相关,与复发、感染发生率或慢性移植物抗宿主病无关。
- 成人第180天CD4计数高于 cutoff 与总生存期、无进展生存期和治疗相关死亡率改善相关,与其他结局无关。
- 儿童患者中未发现CD4计数的临床关联。
核心结论
- 成人造血细胞移植后CD4 T细胞恢复延迟与总生存期降低相关,强调为成人调整移植策略以优化免疫恢复并改善结局的重要性。
研究设计与样本
- 回顾性分析2008至2019年上报国际血液与骨髓移植研究中心的2089例首次异基因造血细胞移植患者,涵盖急性髓系白血病、急性淋巴细胞白血病和骨髓发育异常综合征,要求第100天和第180天有可用的CD4计数。
- 患者中位年龄51岁(范围2-75),按移植物抗宿主病预防方案分为四组:体外T细胞去除(TCD/CD34)、移植后环磷酰胺、单用钙调神经磷酸酶抑制剂(CNI)或CNI联合抗胸腺细胞球蛋白。
主要发现
- 基于生存确定CD4+ T细胞最佳 cutoff 值:儿童(年龄<20岁)第100天为248×10^6/L、第180天为420×10^6/L;成人(年龄>20岁)第100天为104×10^6/L、第180天为115×10^6/L。
- 成人第100天CD4计数与总生存期、无进展生存期和治疗相关死亡率相关,但与复发、感染发生率或慢性移植物抗宿主病无关。
- 成人第180天CD4计数高于 cutoff 与总生存期、无进展生存期和治疗相关死亡率改善相关,但与其他结局无关。
- 儿童患者中未发现CD4计数的临床关联。
关键数值与推荐
- 儿童(年龄<20岁)CD4+ T细胞最佳 cutoff:第100天248×10^6/L,第180天420×10^6/L。
- 成人(年龄>20岁)CD4+ T细胞最佳 cutoff:第100天104×10^6/L,第180天115×10^6/L。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic cell transplantation (allo-HCT) can provide curative treatment for hematologic malignancies but is associated with prolonged lymphopenia that may contribute to an increased risk of infection and relapse, resulting in decreased survival. We hypothesized that patients with rapid and robust CD4 T- and B-cell recovery have improved survival and decreased treatment-related mortality (TRM). A total of 2089 patients were included who underwent first allo-HCT for acute myeloid leukemia/acute lymphoblastic leukemia/myelodysplastic syndrome from 2008 to 2019 reported to the Center for International Blood and Marrow Transplant Research with available CD4 counts at days 100 and 180. Patients (median age, 51 years [range, 2-75]) were categorized into 4 groups based on graft-versus-host disease (GVHD) prophylaxis: ex vivo T-cell depletion (TCD/CD34), posttransplant cyclophosphamide, calcineurin inhibitor alone (CNI), or CNI with antithymocyte globulin. Based upon survival, we could identify optimal cutoff points for CD4+ T cells in pediatric (age of <20 years) patients: 248 × 106/L and 420 × 106/L at days 100 and 180, respectively; and in adult (age of >20 years) patients: 104 × 106/L and 115 × 106/L at days 100 and 180, respectively. In adults, day-100 CD4 count was associated with overall survival (OS), progression-free survival (PFS), and TRM but not relapse, incidence of infections, or chronic GVHD. Similarly, CD4 counts above the cutoff point at day 180 in adults were associated with improved OS, PFS, and TRM but no other outcomes. No clinical associations for CD4 counts were identifiable in pediatric patients. These findings underscore the importance of tailoring transplant strategies for adults to optimize immune recovery and improve patient outcomes.
引用
- Perales MA, Riches M, He N, et al. Delayed T-cell recovery after hematopoietic cell transplantation is associated with decreased overall survival in adults. Blood Adv. 2025. PMID: 40249911. doi:10.1182/bloodadvances.2024015288
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。